Compile Data Set for Download or QSAR
Report error Found 3958 of ic50 for UniProtKB: P00734
TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM14073((2S)-N-[(2S)-1-(1,3-benzothiazol-2-yl)-5-carbamimi...)
Affinity DataKi:  0.000650nM ΔG°:  -17.3kcal/mole IC50: 4.5nMpH: 7.4 T: 2°CAssay Description:Thrombin-catalyzed hydrolysis rates were measured spectrophotometrically using human alpha-thrombin, a chromogenic substrate in aqueous buffer, and a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2007
Entry Details Article
PubMed
TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM50125842(5-amino(imino)methylamino-2-[1-[2-amino-3-phenyl-(...)
Affinity DataIC50: 0.00170nMAssay Description:In vitro inhibitory concentration of compound against human thrombinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2012
Entry Details Article
PubMed
TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM14065((2S)-1-[(2R)-2-amino-3-phenylpropanoyl]-N-[1-(1,3-...)
Affinity DataKi:  0.00550nM ΔG°:  -16.0kcal/mole IC50: 21nMpH: 7.4 T: 2°CAssay Description:Thrombin-catalyzed hydrolysis rates were measured spectrophotometrically using human alpha-thrombin, a chromogenic substrate in aqueous buffer, and a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2007
Entry Details Article
PubMed
TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM14127(2-(5-carbamimidamido-2-{[(2S)-1-[(2R)-2-(methylami...)
Affinity DataKi:  0.00700nM IC50: 5nMAssay Description:Thrombin-catalyzed hydrolysis rates were measured spectrophotometrically using human alpha-thrombin, a chromogenic substrate in aqueous buffer, and a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2007
Entry Details Article
PubMed
TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM50120225(2-{[2-(4-Guanidino-butyrylamino)-3-(4-nitro-phenyl...)
Affinity DataIC50: 0.00800nMAssay Description:Concentration required to inhibit thrombin was determinedMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM254888(US9493472, 11)
Affinity DataIC50: 0.0100nMpH: 7.4 T: 2°CAssay Description:To determine the thrombin inhibition of the substances listed above, a biochemical test system is constructed in which the conversion of a thrombin s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM14076((2S)-N-[(2S)-1-(1,3-benzothiazol-2-yl)-5-carbamimi...)
Affinity DataKi:  0.0180nM ΔG°:  -15.2kcal/mole IC50: 5.30nMpH: 7.4 T: 2°CAssay Description:Thrombin-catalyzed hydrolysis rates were measured spectrophotometrically using human alpha-thrombin, a chromogenic substrate in aqueous buffer, and a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2007
Entry Details Article
PubMed
TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM50228863(1-(2-Methylamino-3-phenyl-propionyl)-pyrrolidine-2...)
Affinity DataIC50: 0.0300nMAssay Description:Concentration required to inhibit thrombin was determinedMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM50096624(3-(4-Amino-cyclohexyl)-2-oxo-3-[((6S,8aS)-4-oxo-2-...)
Affinity DataIC50: 0.100nMAssay Description:In vitro activity against human alpha thrombin was determinedMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM50063555(1-(2-Amino-3,3-diphenyl-propionyl)-pyrrolidine-2-c...)
Affinity DataIC50: 0.100nMAssay Description:Inhibitory activity against thrombinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM254889(US9493472, 12)
Affinity DataIC50: 0.100nMpH: 7.4 T: 2°CAssay Description:To determine the thrombin inhibition of the substances listed above, a biochemical test system is constructed in which the conversion of a thrombin s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM50520683(CHEMBL4476621)
Affinity DataIC50: 0.103nMAssay Description:Inhibition of human thrombin using Z-GPR-AMC as substrate after 30 mins by fluorimetric analysisMore data for this Ligand-Target Pair
In Depth
Date in BDB:
2/23/2021
Entry Details Article
PubMed
TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM14066((2S)-N-[1-(1,3-benzothiazol-2-yl)-5-carbamimidamid...)
Affinity DataKi:  0.120nM ΔG°:  -14.1kcal/mole IC50: 15nMpH: 7.4 T: 2°CAssay Description:Thrombin-catalyzed hydrolysis rates were measured spectrophotometrically using human alpha-thrombin, a chromogenic substrate in aqueous buffer, and a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2007
Entry Details Article
PubMed
TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM14123((2S)-N-[5-carbamimidamido-1-(6-methoxy-1,3-benzoth...)
Affinity DataKi:  0.140nM IC50: 5nMAssay Description:Thrombin-catalyzed hydrolysis rates were measured spectrophotometrically using human alpha-thrombin, a chromogenic substrate in aqueous buffer, and a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2007
Entry Details Article
PubMed
TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM14125((2S)-N-[5-carbamimidamido-1-(6-fluoro-1,3-benzothi...)
Affinity DataKi:  0.150nM IC50: 7.5nMAssay Description:Thrombin-catalyzed hydrolysis rates were measured spectrophotometrically using human alpha-thrombin, a chromogenic substrate in aqueous buffer, and a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2007
Entry Details Article
PubMed
TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM254905(US9493472, 27)
Affinity DataIC50: 0.160nMpH: 7.4 T: 2°CAssay Description:To determine the thrombin inhibition of the substances listed above, a biochemical test system is constructed in which the conversion of a thrombin s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM14068((2S)-N-[1-(1,3-benzothiazol-2-yl)-5-carbamimidamid...)
Affinity DataKi:  0.180nM ΔG°:  -13.8kcal/mole IC50: 48nMpH: 7.4 T: 2°CAssay Description:Thrombin-catalyzed hydrolysis rates were measured spectrophotometrically using human alpha-thrombin, a chromogenic substrate in aqueous buffer, and a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2007
Entry Details Article
PubMed
TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM254904(US9493472, 26)
Affinity DataIC50: 0.190nMpH: 7.4 T: 2°CAssay Description:To determine the thrombin inhibition of the substances listed above, a biochemical test system is constructed in which the conversion of a thrombin s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM50443853(CHEMBL3091519 | US20230391761, Reference 1)
Affinity DataIC50: 0.190nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
US Patent

TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM14071((2S)-1-(2-amino-2-benzylpropanoyl)-N-[1-(1,3-benzo...)
Affinity DataKi:  0.200nM ΔG°:  -13.8kcal/mole IC50: 3.5nMpH: 7.4 T: 2°CAssay Description:Thrombin-catalyzed hydrolysis rates were measured spectrophotometrically using human alpha-thrombin, a chromogenic substrate in aqueous buffer, and a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2007
Entry Details Article
PubMed
TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM254886(US9493472, 9)
Affinity DataIC50: 0.200nMpH: 7.4 T: 2°CAssay Description:To determine the thrombin inhibition of the substances listed above, a biochemical test system is constructed in which the conversion of a thrombin s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM14063((2S)-N-[1-(1,3-benzothiazol-2-yl)-5-carbamimidamid...)
Affinity DataKi:  0.200nM ΔG°:  -13.8kcal/mole IC50: 29nMpH: 7.4 T: 2°CAssay Description:Thrombin-catalyzed hydrolysis rates were measured spectrophotometrically using human alpha-thrombin, a chromogenic substrate in aqueous buffer, and a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2007
Entry Details Article
PubMed
TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM14124((2S)-N-[5-carbamimidamido-1-(6-hydroxy-1,3-benzoth...)
Affinity DataKi:  0.230nM IC50: 3nMAssay Description:Thrombin-catalyzed hydrolysis rates were measured spectrophotometrically using human alpha-thrombin, a chromogenic substrate in aqueous buffer, and a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2007
Entry Details Article
PubMed
TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM254896(US9493472, 18)
Affinity DataIC50: 0.300nMpH: 7.4 T: 2°CAssay Description:To determine the thrombin inhibition of the substances listed above, a biochemical test system is constructed in which the conversion of a thrombin s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM14086((2S)-N-[1-(1,3-benzothiazol-2-yl)-5-carbamimidamid...)
Affinity DataKi:  0.340nM IC50: 38nMAssay Description:Thrombin-catalyzed hydrolysis rates were measured spectrophotometrically using human alpha-thrombin, a chromogenic substrate in aqueous buffer, and a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2007
Entry Details Article
PubMed
TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM14072(2-{[(2R)-1-[(2S)-2-{[1-(1,3-benzothiazol-2-yl)-5-c...)
Affinity DataKi:  0.360nM ΔG°:  -13.4kcal/mole IC50: 29nMpH: 7.4 T: 2°CAssay Description:Thrombin-catalyzed hydrolysis rates were measured spectrophotometrically using human alpha-thrombin, a chromogenic substrate in aqueous buffer, and a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2007
Entry Details Article
PubMed
TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM14126((2S)-N-{5-carbamimidamido-1-[6-(hydroxymethyl)-1,3...)
Affinity DataKi:  0.370nM IC50: 7nMAssay Description:Thrombin-catalyzed hydrolysis rates were measured spectrophotometrically using human alpha-thrombin, a chromogenic substrate in aqueous buffer, and a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2007
Entry Details Article
PubMed
TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM254895(US9493472, 17)
Affinity DataIC50: 0.370nMpH: 7.4 T: 2°CAssay Description:To determine the thrombin inhibition of the substances listed above, a biochemical test system is constructed in which the conversion of a thrombin s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM254911(US9493472, 33)
Affinity DataIC50: 0.380nMpH: 7.4 T: 2°CAssay Description:To determine the thrombin inhibition of the substances listed above, a biochemical test system is constructed in which the conversion of a thrombin s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM14075((2S)-N-[1-(1,3-benzothiazol-2-yl)-5-carbamimidamid...)
Affinity DataKi:  0.460nM ΔG°:  -13.2kcal/mole IC50: 34nMpH: 7.4 T: 2°CAssay Description:Thrombin-catalyzed hydrolysis rates were measured spectrophotometrically using human alpha-thrombin, a chromogenic substrate in aqueous buffer, and a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2007
Entry Details Article
PubMed
TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM50289560(N-((S)-1-Carbamimidoyl-2-hydroxy-piperidin-3-yl)-2...)
Affinity DataIC50: 0.467nMAssay Description:Inhibitory concentration required to inhibit human thrombin enzyme was determinedMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2010
Entry Details Article

TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM254894(US9493472, 16)
Affinity DataIC50: 0.470nMpH: 7.4 T: 2°CAssay Description:To determine the thrombin inhibition of the substances listed above, a biochemical test system is constructed in which the conversion of a thrombin s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM50076074(N-((S)-1-Carbamimidoyl-2-hydroxy-piperidin-3-yl)-2...)
Affinity DataIC50: 0.505nMAssay Description:Concentration required for the in vitro inhibitory activity against human enzyme, thrombin cleavage of the chromogenic substrateMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM50076074(N-((S)-1-Carbamimidoyl-2-hydroxy-piperidin-3-yl)-2...)
Affinity DataIC50: 0.505nMAssay Description:Inhibitory concentration required to inhibit human thrombin enzyme was determinedMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2010
Entry Details Article

TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM254907(US9493472, 29 | US9493472, 30 | US9493472, 31)
Affinity DataIC50: 0.540nMpH: 7.4 T: 2°CAssay Description:To determine the thrombin inhibition of the substances listed above, a biochemical test system is constructed in which the conversion of a thrombin s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM14122((2S)-N-(5-carbamimidamido-1-oxo-1-{3-thia-5-azatri...)
Affinity DataKi:  0.580nM IC50: 60nMAssay Description:Thrombin-catalyzed hydrolysis rates were measured spectrophotometrically using human alpha-thrombin, a chromogenic substrate in aqueous buffer, and a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2007
Entry Details Article
PubMed
TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM50054486(N-[(S)-1-((S)-1-Carbamimidoyl-piperidin-3-ylmethyl...)
Affinity DataIC50: 0.670nMAssay Description:Compound was evaluated for inhibition of amidolytic activity for chromogenic substrate thrombin F11a.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMedPDB3D3D Structure (crystal)
TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM50054498((R)-1-((R)-2-Methylamino-3-phenyl-propionyl)-pyrro...)
Affinity DataIC50: 0.700nMAssay Description:In vitro for inhibition of serine protease thrombin(FIIa).More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM254910(US9493472, 32)
Affinity DataIC50: 0.700nMpH: 7.4 T: 2°CAssay Description:To determine the thrombin inhibition of the substances listed above, a biochemical test system is constructed in which the conversion of a thrombin s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM50054493(N-((S)-3-Carbamimidoyl-2-hydroxy-cyclohexyl)-2-((S...)
Affinity DataIC50: 0.710nMAssay Description:In vitro for inhibition of serine protease thrombin(FIIa).More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM50073429(CHEMBL84575 | CHEMBL82032 | N-((S)-1-Carbamimidoyl...)
Affinity DataIC50: 0.710nMAssay Description:The compound was tested in vitro for inhibitory activity against Coagulation factor IIMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/22/2010
Entry Details Article

TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM50054484(CVS-1778 | N-((S)-1-Formyl-4-guanidino-butyl)-2-((...)
Affinity DataIC50: 0.710nMAssay Description:Compound was evaluated for inhibition of amidolytic activity for chromogenic substrate thrombin F11a.More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM50073429(CHEMBL84575 | CHEMBL82032 | N-((S)-1-Carbamimidoyl...)
Affinity DataIC50: 0.710nMAssay Description:In vitro inhibitory activity against human enzyme thrombinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
11/10/2009
Entry Details Article
PubMed
TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM254892(US9493472, 15)
Affinity DataIC50: 0.720nMpH: 7.4 T: 2°CAssay Description:To determine the thrombin inhibition of the substances listed above, a biochemical test system is constructed in which the conversion of a thrombin s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/16/2017
Entry Details
US Patent

TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM639342(2-(1-Methyl-1H-imidazol-2-yl)ethyl 3-{[(5-chloro-2...)
Affinity DataIC50: 0.740nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
US Patent

TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM14139((2S)-N-[(2S)-1-(1,3-benzothiazol-2-yl)-5-carbamimi...)
Affinity DataKi:  0.780nM IC50: 110nMAssay Description:Thrombin-catalyzed hydrolysis rates were measured spectrophotometrically using human alpha-thrombin, a chromogenic substrate in aqueous buffer, and a...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/5/2007
Entry Details Article
PubMed
TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM639341(2-(1-Methyl-1H-imidazol-5-yl)ethyl 3-[(5-chlorothi...)
Affinity DataIC50: 0.830nMAssay Description:Determination of the Selectivity To demonstrate the selectivity of the substances with respect to thrombin and factor Xa inhibition, the test substan...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2024
Entry Details
US Patent

TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM50234836(CHEMBL4086267)
Affinity DataIC50: 0.840nMAssay Description:Inhibition of human thrombin preincubated for 10 mins followed by Ac-FVR-AMC substrate addition measured every 20s for 10 mins by fluorescence assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/19/2019
Entry Details Article
PubMed
TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM50287790((2S,4R)-1-Acetyl-4-benzyloxy-pyrrolidine-2-carboxy...)
Affinity DataIC50: 0.900nMAssay Description:Inhibition of thrombinMore data for this Ligand-Target Pair
In Depth
Date in BDB:
8/21/2010
Entry Details Article

TargetProthrombin(Human)
Johnson & Johnson Pharmaceutical

LigandPNGBDBM50191108(CHEMBL3974458)
Affinity DataIC50: 0.920nMAssay Description:Inhibition of human thrombin pre-incubated for 10 mins before Ac-FVR-AMC substrate addition and measured after 10 mins by fluorescence based assayMore data for this Ligand-Target Pair
In Depth
Date in BDB:
6/25/2018
Entry Details Article
PubMed
Displayed 1 to 50 (of 3958 total ) | Next | Last >>
Jump to: